News

According to a report by L.E.K Consulting, challenges are unlike other industries’, and adoption of artificial intelligence may be slow. Telemedicine accelerated by COVID-19 could drive uptake.

In this week’s episode of Tuning Into the C-Suite podcast, MHE's Briana Contreras spoke with Sebastian Seiguer, CEO of emocha Mobile Health. The two talked about the key health challenges schools are facing as some are reopening across the country for the '20-'21 school year, how telehealth services like emocha are successfully using telehealth to open schools in a Return to Learn program, and paths forward for our nation’s largest school districts.

The New York Times is reporting that a study volunteer in the U.K. developed transverse myelitis.

One code covers additional supplies and clinical time related to safety protocols. The other covers antibody testing.

Pharma makers expect the treatment to be available within a week.

The COVID-19 pandemic is transforming the way the healthcare industry hands payments.

A new study finds people who go on to be diagnosed with MS are more likely to have experienced a significant stressful life event, but the author cautions against jumping to cause-and-effect conclusions.

The medication boasts a statistically significant improvement in overall survival versus placebo.

Study of the quality of life of psoriatic arthritis patients reveals the added burden of skin symptoms.

Brent James discusses the long-term consequences of COVID-19.

Four initiatives healthcare operators can implement to help their employees deal with the challenges posed by the pandemic.

Brent James, M.D., M.Stat., the quality and patient safety expert, finds fault with singular focus on COVID-19. Watch James' interview in this part two of three video series.

Pro, college, and high school athletes are seeing increasing numbers of COVID-19 infection and potential heart complications that could be career-ending. Ambulatory cardiac monitoring provider InfoBionic says simple and effective remote cardiac monitoring will save lives—and careers.

Brent James, the quality and patient safety expert, sees excess mortality from lack of care for life-threatening conditions other than COVID-19. Watch James' interview in this part one of three video series.

As MCOs contend with more federal and state-level regulations, below are a few adjustments leaders can make to ensure compliance while Medicaid enrollees increase.

A JAMA Oncology viewpoint argues that the COVID-19 pandemic presents a prime opportunity to make clinical trial design and execution more efficient.

The 2020 meeting, presented in a virtual format from its original host city of Amsterdam, The Netherlands, had lots of important science and a record number of viewers.

Plan sponsors should begin evaluation of PBM performance at least a year before the contract expires, say lawyers with expertise in PBM contracting.

Founders of Medicaid had reason to fear that a state-run program would have limited ability to address the needs of vulnerable populations, say authors of Health Affairs piece.

A study from the European Society of Cardiology answers a question about COVID-19: should patients keep taking well-known heart medications?

This week on Tuning Into the C-Suite, Managed Healthcare Executive's Senior Editor, Peter Wehrwein, spoke with Georgetown's Sabrina Corlette, JD. The two discussed the possible motivations behind health insurer announcing premium credits and discounts in recent weeks and months after their profits (net income, for not-for-profits) swelled due to the drop-off in routine healthcare utilization.

deCODE Genetics researchers find that 90% of those diagnosed with SARS-CoV-2 infection have antibodies to the virus four months later.

One study questions the effectiveness of remdesivir past day 10 while others support its expanded use.

The COVID-19 pandemic has led payers and providers to embrace electronic encrypted documents and other technology — and that has fostered greater collaboration between them.

Findings presented at the European Society of Cardiology meeting could open the door to the use of the gout drug as a treatment targeting the underlying inflammation of cardiovascular disease.

This week's FDA updates include an end to a boxed warning for a type 2 diabetes drug, an expanded emergency use authorization due to COVID-19, and another liquid biopsy.

Georgetown’s Sabrina Corlette says the 2021 rates were calculated before the recent announcements about COVID-19 premium relief in this part two of two video series.

COVID-19 may have made clinician burnout even more of problem. AI could help by streamlining workflows.